Skip to content
Search:
Search
Facebook page opens in new window
 
ADCS
Alzheimer's Disease Cooperative Study
ADCSADCS
  • About Us
    • About ADCS
    • Meet the Directors
    • ADCS Cores
    • ADCS Clinical Trials Network
    • ADCS Intervention Selection Committee
    • Steering Committee Voting Members
  • Public & Participant Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Clinical Sites
    • Types of Studies
    • Clinical Trials
    • Lifestyle Interventions
    • Alzheimer’s Study Quilt Project
  • Investigator Resources
    • Publications
    • Study Resources
    • Data Sharing
    • Biospecimen Bank
    • ADCS Instruments
    • Preliminary Proposals
    • Combination Therapy Call OPEN
  • CTMS
    • Clinical Conductor Enterprise
    • Clinical Conductor Site Portals
      • Donate
  • Steering Committee Members
  • Staff Resources
  • DONATE
  • About Us
    • About ADCS
    • Meet the Directors
    • ADCS Cores
    • ADCS Clinical Trials Network
    • ADCS Intervention Selection Committee
    • Steering Committee Voting Members
  • Public & Participant Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Clinical Sites
    • Types of Studies
    • Clinical Trials
    • Lifestyle Interventions
    • Alzheimer’s Study Quilt Project
  • Investigator Resources
    • Publications
    • Study Resources
    • Data Sharing
    • Biospecimen Bank
    • ADCS Instruments
    • Preliminary Proposals
    • Combination Therapy Call OPEN
  • CTMS
    • Clinical Conductor Enterprise
    • Clinical Conductor Site Portals
      • Donate
  • Steering Committee Members
  • Staff Resources
  • DONATE

Daily Archives: February 11, 2019

You are here:
  1. Home
  2. 2019
  3. February
  4. 11

ADCS Director Howard Feldman, MD talks about the T2 Protect trial and a bright future for Alzheimer’s research

Research NewsBy Genny MathewsFebruary 11, 2019
Copyright 2017 Regents of the University of California.
Go to Top